Endocrine (2019) 63:32331
The DECLARE-TIMI 58 trial showed Farxiga users typically lose 3-5 kg (roughly 4-6 lb) in year one, with a plateau at maintenance levels thereafter
Because SG became widespread after 2014, the data set in humans is smaller than that for RYGB, but several [284,285,286] though not all [287,288,289] studies suggest SG approximates RYGB in raising AUD risk, particularly for de novo post-operative alcohol problems
Creative Commons CC-BY license, Obesity is associated with numerous health complications, including type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease (MASLD), and certain cancers